Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer

被引:1
作者
Schneider, J
Velcovsky, HG
Morr, H
Katz, N
Neu, K
Eigenbrodt, E
机构
[1] Univ Giessen, Inst & Poliklin Arbeits & Sozialmed, D-35385 Giessen, Germany
[2] Univ Giessen Klinikum, Med Klin 2, D-35392 Giessen, Germany
[3] Pneumol Klin Waldhof Elgershausen, D-35753 Greifenstein, Germany
[4] Univ Giessen, Inst Klin Chem & Pathobiochem, D-35385 Giessen, Germany
[5] Univ Giessen, Inst Biochem & Endokrinol, D-35385 Giessen, Germany
关键词
tumor M2-pyruvate kinase; CEA; CYFRA; 21; NSE; SCC; lung cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study presents data comparing the new tumor marker Tumor M2-PK with CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancel: Tumor M2-PK is quantitatively detectable in EDTA-plasma with a sensitive ELISA. The results of the tumor marker test were compared with respect to the differ ent histological tumor types and with the tumor staging. So far 144 newly diagnosed lung cancer patients were included. Significantly elevated tumor marker concentrations were found with progressive tumor stages. The best correlation with the tumor stage was observed for Tumor M2-PK and CYFRA 21-1. Comparison of the sensivities in the detection of lung cancel indicated that the Tumor M2-PK-test (sensitivity: 58%) is more efficient than the CEA-Test (sensitivity: 39%) or CYFRA 21-1 (sensitivity: 48%). Generally higher sensitivity for non-small cell lung cancer only was shown for Tumor M2-PK (sensivity: 65%), CEA (sensitivity: 42%) and CYFRA 21-1 (sensitivity: 58%). For small-cell lung cancer the marker NSE was more sensitive than all other markers. Initial follow-np studies indicate that Tumor M2-PK and CYFRA 21-1 can be used to monitor disease with tumor progression or regression during chemotherapy. The present data indicated that Tumor M2-PK could be a valuable tumor marker for the detection of lung cancer.
引用
收藏
页码:5053 / 5058
页数:6
相关论文
共 14 条
[1]  
BALINSKY D, 1984, CANCER RES, V44, P1058
[2]  
BRINCK U, 1994, VIRCHOWS ARCH, V424, P177
[3]  
Chambers JM., 1983, WADSWORTH
[4]  
EIGENBRODT E, 1992, Critical Reviews in Oncogenesis, V3, P91
[5]  
Eigenbrodt E, 1997, ANTICANCER RES, V17, P3153
[6]  
Hugo F, 1999, ANTICANCER RES, V19, P2753
[7]  
IBSEN KH, 1982, CANCER RES, V42, P888
[8]   The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy [J].
Mazurek, S ;
Boschek, CB ;
Eigenbrodt, E .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1997, 29 (04) :315-330
[9]  
Oremek G. M., 1995, Atemwegs- und Lungenkrankheiten, V21, P340
[10]  
Oremek GM, 2000, ANTICANCER RES, V20, P5095